- Stocks
- Healthcare
- NASDAQ: ARNA

Price (delayed)

$80.70

Market cap

$4.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.09

Enterprise value

$4.28B

ARNA's debt is down by 7% YoY and by 2.1% from the previous quarter

The quick ratio has declined by 20% since the previous quarter but it has increased by 5% year-on-year

ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY

Arena Pharmaceuticals's net income has plunged by 167% YoY and by 7% from the previous quarter

The EPS has shrunk by 163% YoY and by 3.4% QoQ

What are the main financial stats of ARNA

Market
Valuations
Earnings

Shares outstanding

58.16M

Market cap

$4.69B

Enterprise value

$4.28B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.98

Price to sales (P/S)

1,419.84

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,303.38

Revenue

$3.28M

EBIT

-$366.33M

EBITDA

-$362.55M

Free cash flow

-$310.71M

Per share
Balance sheet
Liquidity

EPS

-$7.09

Free cash flow per share

-$5.38

Book value per share

$20.29

Revenue per share

$0.06

TBVPS

$22.08

Total assets

$1.28B

Total liabilities

$105.62M

Debt

$46.62M

Equity

$1.17B

Working capital

$1.15B

Debt to equity

0.04

Current ratio

23.17

Quick ratio

22.5

Net debt/EBITDA

1.14

Margins
Efficiency
Dividend

EBITDA margin

-11,039.9%

Gross margin

100%

Net margin

-11,293.7%

Operating margin

-11,729.9%

Return on assets

-30.4%

Return on equity

-33.2%

Return on invested capital

-42.5%

Return on capital employed

-29.9%

Return on sales

-11,155.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Arena Pharmaceuticals stock price performed over time

Intraday

0.25%

1 week

4.82%

1 month

11.46%

1 year

72.92%

YTD

5.04%

QTD

5.04%

How have Arena Pharmaceuticals's revenue and profit performed over time

Revenue

$3.28M

Gross profit

$3.28M

Operating income

-$385.21M

Net income

-$370.88M

Gross margin

100%

Net margin

-11,293.7%

The operating income has dropped by 172% year-on-year and by 5% since the previous quarter

Arena Pharmaceuticals's net income has plunged by 167% YoY and by 7% from the previous quarter

The gross profit has plunged by 100% YoY and by 29% from the previous quarter

The revenue has dropped by 100% year-on-year and by 29% since the previous quarter

What is Arena Pharmaceuticals's growth rate over time

What is Arena Pharmaceuticals stock price valuation

P/E

N/A

P/B

3.98

P/S

1,419.84

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,303.38

The EPS has shrunk by 163% YoY and by 3.4% QoQ

The P/B is 69% less than the 5-year quarterly average of 12.7 but 53% more than the last 4 quarters average of 2.6

ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY

ARNA's price to sales (P/S) is 135% more than its last 4 quarters average of 603.2

The revenue has dropped by 100% year-on-year and by 29% since the previous quarter

How efficient is Arena Pharmaceuticals business performance

ARNA's return on invested capital has dropped by 164% year-on-year and by 15% since the previous quarter

ARNA's ROE has plunged by 163% YoY and by 7% from the previous quarter

ARNA's ROA has dropped by 162% year-on-year and by 6% since the previous quarter

The ROS has shrunk by 51% QoQ

What is ARNA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ARNA.

How did Arena Pharmaceuticals financials performed over time

The quick ratio has declined by 20% since the previous quarter but it has increased by 5% year-on-year

ARNA's current ratio is down by 19% from the previous quarter but it is up by 6% YoY

ARNA's debt is 96% less than its equity

ARNA's debt is down by 7% YoY and by 2.1% from the previous quarter

ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.